NASDAQ:BIVI

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
····

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3

BioVie shares closed at $1.35, up 3.05%, after the company said the last patient visit in its SUNRISE-PD Phase 2 Parkinson’s trial was completed. The company expects topline data in Q3 2026 for its experimental drug bezisterim. Trading volume was 19,735 shares, well below average. The trial enrolled 57 early-stage patients and tested motor and non-motor outcomes.
May 21, 2026

Stock Market Today

  • Guzman Y Gomez Shares Plunge 37% but Show Strong Growth Prospects
    May 29, 2026, 9:18 PM EDT. Guzman Y Gomez Ltd (ASX: GYG), an Australian Mexican restaurant chain, has seen its shares fall over 37% in the past year and more than 55% since December 2024. Despite the volatility, the company has ambitious growth plans, aiming to expand its Australian restaurant count from 242 to 1,000 within 20 years. It reported 20% network sales growth and 6.6% comparable sales growth in Australia in Q3 FY26, with underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) expected to rise 29% year-on-year to about AUD 85 million. Asian operations, particularly in Japan and Singapore, are growing at 15% per year but remain a small portion of total sales. Rising profit margins could further boost future earnings, making GYG a notable opportunity outside the volatile tech sector.